Latest news with #TelixPharmaceuticals
News.com.au
23-07-2025
- Business
- News.com.au
Lunch Wrap: Miners muscle the ASX higher, but Telix sinks on SEC subpoena
Miners lift ASX as iron ore pops again Telix gets US SEC subpoena, shares tank 
 Woodside flexes LNG muscle, Paladin fizzles The ASX was up 0.6% at lunch time in the eastern states, riding a wave of momentum from the mining giants once again. Iron ore has been on a tear since yesterday, jumping another 2% this morning to a five-month high. Traders are frothing over fresh China's supply-side steel reforms, as well as news they're building mega dams up in Tibet. Rio Tinto (ASX:RIO), BHP (ASX:BHP) and Fortescue (ASX:FMG) once again charged higher off the back this news. Meanwhile, cancer imaging stock Telix Pharmaceuticals (ASX:TLX) faceplanted straight into the dirt, down by as much as 16% after revealing it had been subpoenaed by the US SEC over disclosures tied to its prostate cancer therapies. The company says it's cooperating fully, but investors weren't in the mood for nuance; they dumped the stock, sending it to its lowest level since last November. It's not the first time Telix has looked like a stock on the cusp of global stardom. It just launched Gozellix in the US, and the Illuccix pipeline remains strong. But an SEC inquiry, even if it's just a "fact-finding" one, usually has a nasty habit of stopping momentum. This is where things stood at about 1pm AEST: In other large caps news, Iluka Resources (ASX:ILU) climbed 2% after hitting full-year zircon production guidance six months early. Iluka didn't hand out fresh guidance for next quarter though, blaming the mess of global tariffs and trade spats. Woodside Energy Group's (ASX:WDS) quarterly update also packed some punch. WDS said it's pushing ahead hard with its Scarborough and Trion projects (86% and 35% complete respectively) and just offloaded a 40% chunk of its Louisiana LNG venture to Stonepeak for US$5.7 billion. CEO Meg O'Neill called it a key play in positioning Woodside as a 'global LNG powerhouse.' Uranium play Paladin Energy (ASX:PDN), on the other hand, took a hit, down 9% after releasing updated production forecasts for its Langer Heinrich uranium mine. Paladin's guidance, 4 to 4.4 million pounds of U3O8, were decent, but the market had hoped for something flashier. Argonaut had forecast 5.83Mlb, with costs up to US$10/lb higher than its prediction. And over at oil & gas mob Karoon Energy (ASX:KAR), CEO Julian Fowles will be stepping down by mid-2026 as the company prepares to shift its centre of gravity from Melbourne to Brazil and the US. Karoon's board is now hunting for a Houston-based replacement, and its shares dipped 0.6% on the news. ASX SMALL CAP WINNERS Here are the best performing ASX small cap stocks for July 23 : Security Description Last % Volume MktCap GTE Great Western Exp. 0.018 64% 5,921,161 $6,245,337 CDE Codeifai Limited 0.027 50% 41,056,863 $8,494,218 FAU First Au Ltd 0.006 50% 27,932,433 $8,305,165 HLX Helix Resources 0.002 50% 64,088 $3,364,194 RBR RBR Group Ltd 0.002 50% 4,365,000 $3,120,285 ATS Australis Oil & Gas 0.009 29% 7,877,481 $9,226,437 OPL Opyl Limited 0.027 29% 1,998,643 $5,161,135 GGE Grand Gulf Energy 0.003 25% 287,929 $5,640,850 ALY Alchemy Resource Ltd 0.006 20% 667,502 $5,890,381 AUR Auris Minerals Ltd 0.006 20% 84,033 $2,383,130 LMG Latrobe Magnesium 0.019 19% 7,660,479 $42,025,441 CR3 Core Energy Minerals 0.013 18% 1,226,026 $4,343,319 NOX Noxopharm Limited 0.080 18% 601,898 $19,872,181 AON Apollo Minerals Ltd 0.007 17% 72,800 $5,570,741 CCO The Calmer Co Int 0.004 17% 1,050,178 $9,034,060 FMR FMR Resources Ltd 0.378 16% 112,103 $8,781,221 RML Resolution Minerals 0.080 16% 13,670,406 $45,909,045 SMX Strata Minerals 0.015 15% 1,372,935 $3,183,078 PGY Pilot Energy Ltd 0.012 15% 8,327,314 $21,586,600 ICR Intelicare Holdings 0.016 14% 62,500 $6,806,634 IPT Impact Minerals 0.008 14% 9,952,231 $27,953,310 KRR King River Resources 0.008 14% 200,000 $10,372,165 CNQ Clean Teq Water 0.240 14% 90,600 $15,170,884 AAM Aumegametals 0.041 14% 1,159,232 $21,817,825 Codeifai (ASX:CDE) has added former Nvidia AI expert Rafael Possas to its advisory panel, as it gets ready to roll out its QuantumAI Secure platform. Possas, who helped build Alexa and now heads up machine learning at Canva, joins Codeifai's growing panel of tech heavyweights with experience at OpenAI, WhatsApp and Binance. It's another sharp move as Codeifai pushes deeper into AI, quantum security and global commercialisation. First Au (ASX:FAU) has kicked off a 3000m diamond drilling program at its Nimba Gold Project in Liberia, following a month-long mapping campaign led by director Lei Shi. The drilling aims to confirm structural interpretations around a key Hamak Gold hole, and test new targets spotted during mapping. It's targeting the dip, depth and strike of potential gold zones, with core re-logging from previous holes also underway. Pilot Energy (ASX:PGY) has kicked off a formal farmout process for its massive WA-481P permit in the offshore Perth Basin, targeting a partner to help drill the 1.1 TCF Leander Gas Prospect. The prospect's ready to go, with direct access to WA's domestic gas market via existing infrastructure. With gas demand rising and delays hitting rival projects, Pilot reckons it's got a fast-track, high-impact play on its hands. ASX SMALL CAP LOSERS Here are the worst performing ASX small cap stocks for July 23 : Code Name Price % Change Volume Market Cap EEL Enrg Elements Ltd 0.001 -50% 385,807 $6,507,557 RIM Rimfire Pacific 0.018 -25% 735,910 $60,621,453 SCP Scalare Partners 0.130 -24% 100,050 $7,111,954 GLL Galilee Energy Ltd 0.009 -18% 909,666 $7,779,122 ANO Advance Zinctek Ltd 0.915 -17% 6,274 $68,910,718 CUL Cullen Resources 0.005 -17% 1,692,777 $4,160,411 ENT Enterprise Metals 0.003 -17% 200,001 $4,113,952 PRM Prominence Energy 0.003 -17% 200,000 $1,459,411 SPQ Superior Resources 0.005 -17% 3,700,000 $14,225,896 TFL Tasfoods Ltd 0.005 -17% 100,000 $2,622,573 ENV Enova Mining Limited 0.006 -14% 3,195,749 $10,203,200 IPB IPB Petroleum Ltd 0.006 -14% 10,000 $4,944,821 SPX Spenda Limited 0.006 -14% 515,855 $32,306,508 IND Industrialminerals 0.130 -13% 30,465 $12,048,375 HTG Harvest Tech Grp Ltd 0.014 -13% 1,094,377 $14,544,293 OMG OMG Group Limited 0.007 -13% 1,542,151 $5,826,359 RLG Roolife Group Ltd 0.004 -13% 161,900 $6,371,125 EMU EMU NL 0.021 -13% 337,322 $5,069,963 TLX Telix Pharmaceutical 22.140 -12% 4,518,579 $8,500,584,362 AAJ Aruma Resources Ltd 0.008 -11% 1,000,000 $2,951,465 KGD Kula Gold Limited 0.008 -11% 3,716,355 $8,291,283 RDG Res Dev Group Ltd 0.008 -11% 789,175 $26,557,723 ATX Amplia Therapeutics 0.255 -11% 5,985,655 $110,771,711 IN CASE YOU MISSED IT Bubalus Resources (ASX:BUS) has spotted some compelling Fosterville-style targets at the Crosbie North gold-antimony prospect within its Crosbie project in the heart of the Victorian Goldfields. Theta Gold Mines (ASX:TGM) remains undervalued despite the potential for early gold production from its 6.1Moz Transvaal Gold Mining Estates project. West Wits Mining (ASX:WWI) ' s Qala Shallows just got a major upgrade, with revenue and cash flow surging and payback time slashed as lender talks roll on. LAST ORDERS Miramar Resources (ASX:M2R) has launched a share purchase plan to raise $1m, with the goal of accelerating drilling at the Mile gold prospect within Miramar's 80%-owned Gidji JV project. Management says M2R is looking to determine the scale of the 8 Mile prospect as quickly as possible. QPM Energy (ASX:QPM) has wrapped up an oversubscribed share purchase plan after scaling the capital raise up to $7m to include interested shareholders. The fresh cash will go to accelerating the Isaac Power Station workstreams and initiatives directed at growing gas supply. Verity Resources (ASX:VRL) has a drill rig ready to roll at the Monument gold project, poised to target a resource upgrade for the tenure's 154,000oz resource. The drilling program will initially focus on the larger Korong deposit before moving to the Waihi deposit. Trigg Minerals (ASX:TMG) is working to produce a conceptual study for processing antimony concentrate at its Antimony Canyon project using Metso's proprietary Ausmelt TSLs melting technology. The study will assess a smelter flowsheet concept aligned to produce 3000-5000 tonnes per year of 99.65% purity antimony ingot. ClearVue (ASX:CPV) has entered a two-year collaboration with erbas, a prominent sustainability engineering and consulting company, to integrate ClearVue solar façade solutions, working to support carbon neutral and net zero goals in the built environment. Altech Battery's (ASX:ATC) CERENERGY battery funding is tracking well, with a major European bank close to signing on after final site visits. It's also progressing a federal guarantee and looking for a 49% strategic partner, with offtake deals already lined up. At Stockhead, we tell it like it is. While Miramar Resources, QPM Energy, Verity Resources, Trigg Minerals, West Wits Mining, Altech Battery and ClearVue are Stockhead advertisers, they did not sponsor this article.
News.com.au
23-07-2025
- Business
- News.com.au
Health Check: Aussie biotechs are navigating a US regulatory minefield
Telix faces unwanted US regulatory attention – but it's not alone Amplia raises $25 million, with another $2.5 million to go A home-grown uni biotech innovation shines again Telix Pharmaceuticals (ASX:TLX) shares this morning slumped up to 16% on news that the radiopharmacy play has attracted unwanted attention from the Securities and Exchange Commission (SEC). But the company is no Robinson Crusoe, in that US regulatory and legal glitches pose a regular minefield for ASX biotechs doing business there. The companies watchdog has subpoenaed 'various documents and information'. These mainly relate to the company's disclosures about its prostate cancer therapeutic program. 'The company is fully cooperating with the SEC and is in the process of responding to the information request,' Telix says. 'At this stage, this matter is a fact-finding request'. Telix adds the SEC's entreaty does not mean that Telix has violated US security laws 'or that the SEC has a negative opinion of any person, entity or security'. Barring more detail, the episode sounds like a case of 'probably nothing or very much something'. Overnight, Nasdaq investors were more chill about the affair, marking Telix shares only marginally lower. At the very least, the SEC's nosing around is likely to distract management from the company's busy agenda. 'In our experience of similar matters, these investigations tend to drag on for years without resolution,' broker Jefferies says. Trouble and strife Other ASX biotechs in the US have run into the odd bit of strife over patent disputes and regulatory interventions. ResMed (ASX:RMD) regularly parries with rivals Fisher & Paykel Healthcare (ASX:FPH) and Philips Respironics over sleep apnoea patents. In 2018 a jury ordered Cochlear (ASX:COH) to pay US$268 million in damages for a patent infringement. The charitable Alfred E. Mann Foundation lodged the action. In 2020 Cochlear lost an appeal. In 2013 CSL (ASX:CSL) paid US$64 million to settle an antitrust class action lodged by hospital groups. 'Business as usual' Telix says it will continue with the prostate cancer program. The SEC action also will not affect its nearer-stage imaging programs for kidney and brain cancers. Telix also reported June quarter revenue of US$204 million, 63% higher year on year, whilst maintaining calendar 2025 revenue guidance of US$770-800 million. This revenue derived mainly from Telix's prostate cancer imaging agent, Illucix. 'Dose volumes for Illuccix rose 7% quarter-on-quarter in the US, reinforcing the strength of our market position and continued customer demand,' Telix co-founder and CEO Dr Chris Behrenbruch says. He adds that 'despite emerging competitive pricing pressure', Telix has 'effective strategies' to maintain average selling prices. Next month, Telix lifts the kimono on June (first) half earnings. Jefferies expects a $50.6 million net profit, with a calendar 2025 tally of $88.3 million. Interestingly, this is a decline on the previous year's US$105.4 million, but the firm plugs in US$183 million for calendar 2026. Perhaps they lost our phone number? Speaking of US regulatory glitches, stroke drug developer Argenica Therapeutics (ASX:AGN) is yet to hear back from the US Food and Drug Administration (FDA) as to why the agency plonked a 'clinical hold' on its US trial plans. On June 10 Argenica said the FDA had deemed the company's supportive material as not being adequate to support its Investigational New Drug application. The trial was aimed at approval under the FDA's fast-track route. Argenica expected to hear back from the FDA within 30 days, but the agency's 'resourcing challenges' have blown out this timeline. In the meantime, Argenica is on track to report topline results from its local, proof-of-concept trial in the current quarter. The 92-patient phase II study tests Argenica's candidate ARG-007, in view of safety and preliminary efficacy in ischaemic (blockage) stroke patients. Courtesy of $4 million of government and private grants, Argenica is also investigating the 'potential utility' of ARG-0007 for other neurological conditions, including traumatic brain injury. Argenica disclosed June quarter cash burn of $2.36 million and a closing cash balance of $10.5 million. Nyrada advances heart protection trial In other trial news, Nyrada (ASX:NYR) is advancing its locally developed drug Xolatryp into phase IIa stage. Xolatryp targets the unmet need of protecting the heart following cardiac injury where patients are at high risk of tissue damage. Nyrada notes there's been no significant new cardiac drug developed for more than two decades. Xolatryp could become the first drug of its kind to protect the heart actively from ischemia-reperfusion injury. Nyrada anticipates a randomised, double-blind, placebo-controlled study, enrolling 150 subjects. These patients have acute myocardial infarction undergoing percutaneous coronary intervention (stenting). The company hopes to kick off the study in the March quarter of 2026. We now have Ample-ia funds, says cancer drug developer Prostate cancer drug hopeful Amplia (ASX:ATX) has raised $25 million in an institutional placement and is eyeing a further $2.5 million in a share purchase plan. The deed was done at 23 cents, a 19% discount to last Friday's 'frozen' price ahead of a trading halt. Amplia shares have been on a tear on the back of remarkable phase II results, covering patients with advanced metastatic forms of the deadly disease. Last month Amplia reported 17 partial responses, which meant the tumour size shrunk by at least 30%. Two of the 55 patients reported a complete response, which pretty much means a – can we say it? – cure. Amplia now plans a US trial combining Amplia's candidate AMP-945 with a different chemotherapy. The raising takes Amplia's cash to $42.7 million, including $8.2 million of expected R&D tax refunds. Don't forget who invented it Sanofi's $2.5 billion purchase of vaccine tech outfit Vicebio again highlights the role of Australian universities as a springboard for money-making life sciences ideas. The Paris-based Big Pharma is paying up to US$1.6 billion for the UK-based Vicebio and its so-called molecular clamp technology. The deal involves an upfront payment of US$1.15 billion, with regulatory milestones of US$450 million. Discovered at the University of Queensland (UQ), the clamp stabilises viral proteins enabling the immune system to respond to them more effectively. The upshot is the quicker development of fully liquid combination vaccines that can be stored at fridge temperatures. Vicebio was formed in 2018 to develop the clamp to make vaccines against life-threatening respiratory viral infections. During the pandemic, Vicebio had a stab at a Covid-19 vaccine. Courtesy of a US$100 million Series B financing last year, Vicebio's investors include Goldman Sachs Alternatives, Avoro Ventures and Venbio Partners. Uniquest, UQ's commercialisation arm has an unquantified direct investment and benefits from a licensing arrangement. Uniquest formed more than 130 start-ups, which went on to raise more than $1 billion and glean $86 million in product sales. This included licensing the UQ-invented cervical cancer vaccine Gardasil. The UQ bright sparks responsible for the molecular clamp are professors Paul Young, Daniel Watterson and Keith Chappell. UQ describes the deal as 'the largest involving a company that is commercialising intellectual property from an Australian university.'
Bloomberg
23-07-2025
- Business
- Bloomberg
Telix Shares Drop as SEC Probes Disclosures Tied to Prostate Cancer Drug Pipeline
Telix Pharmaceuticals Ltd. slumped as much as 16%, the most in 21 months, after the Australian developer of radioactive drugs said it received a subpoena from the US Securities and Exchange Commission seeking information about disclosures related to its prostate cancer therapeutic candidates. The Melbourne-based company said it's cooperating with the SEC and is in the process of responding to the request, according to a statement Wednesday. The update came alongside Telix's second-quarter results, which showed a 63% jump in revenue, even as its top-selling product Illuccix faced ongoing price pressure.
Sky News AU
23-07-2025
- Business
- Sky News AU
ASX 200 jumps while Commonwealth Bank of Australia nosedives before recovering after suffering its worst day since April
The ASX 200 has jumped on Wednesday while the index's largest company plummeted before recovering its losses following a wipeout on Tuesday. The bourse jumped 0.3 per cent in the first 70 minutes of trading. Commonwealth Bank of Australia plunged about one per cent before more than recovering after suffering its worst day since April on Tuesday when the bank shed more than three per cent. CBA's dive follows it soaring more than 45 per cent in the 12 months to the end of June, boosting its market cap to about $300b before starting to fall. Meanwhile, Telix Pharmaceuticals has plummeted 15.1 per cent after revealing the US Securities and Exchange Commission issued it a subpoena for more information on disclosures about its prostate cancer therapies. Energy giant Woodside is up 1.8 per cent after reporting a jump in its oil production to 50 million barrels in the second quarter of 2025. Aluminium producer Alcoa Corporation has added four per cent, hardware manufacturer James Hardie is up 4.5 per cent and Whitehaven Coal has surged 4.2 per cent. It follows the index rising on Tuesday before almost completely undoing the gain and finishing up about 0.1 per cent. The performance on Wall Street was mixed with the Dow Jones rising 0.4 per cent, the S&P 500 adding 0.1 per cent and the Nasdaq sinking 0.4 per cent on Tuesday. London's FTSE 250 Index and the STOXX Europe 600 both sank 0.4 per cent while Germany's DAX fell 1.1 per cent. Since trading began on Wednesday, New Zealand's NZX 50 index is down 0.5 per cent and Japan's Nikkei 225 has soared 1.9 per cent.
AU Financial Review
22-07-2025
- Business
- AU Financial Review
Telix subpoenaed by US regulator over cancer therapy
Cancer diagnostic giant Telix Pharmaceuticals says the US Securities and Exchange Commission had issued it with a subpoena seeking information about disclosure related to the development of the company's prostate cancer therapies. Melbourne-based Telix said on Tuesday it had notified the Australian Securities and Investments Commission about the subpoena, which it called a 'fact-finding request'.
